These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29316137)

  • 21. [Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
    Alonso Fernández M
    Semergen; 2018 Jun; 44 Suppl 1():26-32. PubMed ID: 30322470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
    Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
    Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
    Kunutsor SK; Seidu S; Khunti K
    Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cardiovascular effects of new non-insulinic anti-diabetes drugs].
    Dieuzeide G; Puchulu F; Sanabria H; Sinay I
    Medicina (B Aires); 2018; 78(3):185-193. PubMed ID: 29940545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
    Laffin LJ; Bakris GL
    Diabetes Obes Metab; 2018 Jun; 20(6):1335-1336. PubMed ID: 29424470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
    Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Vettor R; Inzucchi SE; Fioretto P
    Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifactorial aspects of the treatment of the type II diabetic patient.
    Colwell JA
    Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.
    Stähli BE; Gebhard C; Tardif JC
    Curr Cardiol Rep; 2015 Jul; 17(7):608. PubMed ID: 26031672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.
    Paneni F
    Diab Vasc Dis Res; 2014 Jan; 11(1):5-10. PubMed ID: 24254974
    [No Abstract]   [Full Text] [Related]  

  • 37. Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes.
    Khunti K; Bellary S; Karamat MA; Patel K; Patel V; Jones A; Gray J; Shepherd P; Hanif W;
    Diabet Med; 2017 Jan; 34(1):64-68. PubMed ID: 26926478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk.
    Levine JP
    J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.